{"id":"F2021L00482","name":"Statement of Principles concerning open-angle glaucoma (Balance of Probabilities) (No. 50 of 2021)","slug":"statement-of-principles-concerning-open-angle-glaucoma-balance-of-probabilities-no-50-of-2021","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":440822,"registerId":"F2021L00482-fast-fetch-1775956316173","compilationNumber":null,"startDate":"2026-04-12","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Statement of Principles concerning open-angle glaucoma (Balance of Probabilities) (No. 50 of 2021)","content":"---\nmeta-content-style-type: text/css\nmeta-content-type: application/xhtml+xml; charset=utf-8\nmeta-generator: Aspose.Words for .NET 20.2\n---\n\n?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\"?>\n\n\n\n \n\nStatement of Principles\n\nconcerning\n\nOPEN-ANGLE GLAUCOMA (Balance of Probabilities)\n\n(No. 50 of 2021)\n\nThe Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(3) of the Veterans' Entitlements Act 1986.\n\n \n\nDated 23 April 2021\n\n \n\n \n\n \n\n \n\n \n\n| The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:
|\n| --- |\n|
Professor Nicholas Saunders AO
Chairperson
|\n\n\n \n\n \n\n\nContents\n\n1 Name\n\n2 Commencement\n\n3 Authority\n\n4 Repeal\n\n5 Application\n\n6 Definitions\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n8 Basis for determining the factors\n\n9 Factors that must exist\n\n10 Relationship to service\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nSchedule 1 - Dictionary\n\n1 Definitions\n\n \n\n\n\n\n1 Name\n\nThis is the Statement of Principles concerning open-angle glaucoma (Balance of Probabilities) (No. 50 of 2021).\n\n2 Commencement\n\n This instrument commences on 24 May 2021.\n\n3 Authority\n\nThis instrument is made under subsection 196B(3) of the Veterans' Entitlements Act 1986.\n\n4 Repeal\n\nThe Statement of Principles concerning open-angle glaucoma No. 28 of 2012 (Federal Register of Legislation No. F2012L00459) made under subsections 196B(3) and (8) of the VEA is repealed.\n\n5 Application\n\nThis instrument applies to a claim to which section 120B of the VEA or section 339 of the Military Rehabilitation and Compensation Act 2004 applies.\n\n6 Definitions\n\nThe terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n(1) This Statement of Principles is about open-angle glaucoma and death from open-angle glaucoma.\n\nMeaning of open-angle glaucoma\n\n(2) For the purposes of this Statement of Principles, open-angle glaucoma:\n\n(a) means an acquired, progressive optic neuropathy involving characteristic optic disc abnormalities and associated visual field defects, occurring in the presence of an open iridocorneal angle and usually associated with raised intraocular pressure; and\n\n(b) includes normal tension glaucoma; and\n\n(c) excludes congenital, infantile or development glaucomas.\n\nNote 1: Open-angle glaucoma may be primary, or secondary to another eye disorder.\n\nNote 2: Open-angle glaucoma may be asymptomatic until the optic nerve damage is severe.\n\n(3) While open-angle glaucoma attracts ICD‑10‑AM code H40.1, in applying this Statement of Principles the meaning of open-angle glaucoma is that given in subsection (2).\n\n(4) For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.\n\nDeath from open-angle glaucoma\n\n(5) For the purposes of this Statement of Principles, open-angle glaucoma, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's open-angle glaucoma.\n\nNote: terminal event is defined in the Schedule 1 - Dictionary.\n\n8 Basis for determining the factors\n\nOn the sound medical‑scientific evidence available, the Repatriation Medical Authority is of the view that it is more probable than not that open-angle glaucoma and death from open-angle glaucoma can be related to relevant service rendered by veterans or members of the Forces under the VEA, or members under the MRCA.\n\nNote: MRCA, relevant service and VEA are defined in the Schedule 1 - Dictionary.\n\n9 Factors that must exist\n\nAt least one of the following factors must exist before it can be said that, on the balance of probabilities, open-angle glaucoma or death from open-angle glaucoma is connected with the circumstances of a person's relevant service:\n\n(1) having glucocorticoid therapy as specified, before the clinical onset of open-angle glaucoma, and where the glucocorticoid therapy as specified has ceased, the last dose of the therapy was received within the three months before the clinical onset of open-angle glaucoma;\n\nNote: glucocorticoid therapy as specified is defined in the Schedule 1 - Dictionary.\n\n(2) having uveitis, scleritis or episcleritis at the time of the clinical onset of open-angle glaucoma;\n\nNote: uveitis, scleritis and episcleritis are defined in the Schedule 1 - Dictionary.\n\n(3) having:\n\n(a) a benign or malignant neoplasm; or\n\n(b) a non-neoplastic lesion;\n\nof the affected eye at the time of the clinical onset of open-angle glaucoma;\n\nNote 1: Examples of a benign or malignant neoplasm include lymphoma, trabecular meshwork melanoma, choroidal metastasis and retinoblastoma.\n\nNote 2: Examples of a non-neoplastic lesion include cyst, ocular haemorrhage (including ghost cells), leakage of lens protein or lens particles and vascular malformation or thrombosis.\n\n(4) having growth of new blood vessels (neovascularisation) of the iridocorneal angle due to a condition or procedure involving the affected eye from the specified list of conditions or procedures, before the clinical onset of open-angle glaucoma;\n\nNote: specified list of conditions or procedures is defined in the Schedule 1 - Dictionary.\n\n(5) having trauma to the affected eye before the clinical onset of open-angle glaucoma;\n\nNote: trauma is defined in the Schedule 1 - Dictionary.\n\n(6) having sympathetic ophthalmia at the time of the clinical onset of open-angle glaucoma;\n\nNote: sympathetic ophthalmia is defined in the Schedule 1 - Dictionary.\n\n(7) having intraocular surgery to the affected eye before the clinical onset of open-angle glaucoma;\n\n(8) undergoing a course of therapeutic radiation for cancer, where the affected eye was in the field of radiation, before the clinical onset of open-angle glaucoma;\n\n(9) having:\n\n(a) eye disease associated with Graves' disease; or\n\n(b) hypothyroidism\n\nwithin the 12 months before the clinical onset of open-angle glaucoma;\n\n(10) having glucocorticoid therapy as specified, before the clinical worsening of open-angle glaucoma, and where the glucocorticoid therapy as specified has ceased, the last dose of the therapy was received within the three months before the clinical worsening of open-angle glaucoma;\n\nNote: glucocorticoid therapy as specified is defined in the Schedule 1 - Dictionary.\n\n(11) having uveitis, scleritis or episcleritis at the time of the clinical worsening of open-angle glaucoma;\n\nNote: uveitis, scleritis and episcleritis are defined in the Schedule 1 - Dictionary.\n\n(12) having:\n\n(a) a benign or malignant neoplasm; or\n\n(b) a non-neoplastic lesion;\n\nof the affected eye at the time of the clinical worsening of open-angle glaucoma;\n\nNote 1: Examples of a benign or malignant neoplasm include lymphoma, trabecular meshwork melanoma, choroidal metastasis and retinoblastoma.\n\nNote 2: Examples of a non-neoplastic lesion include cyst, ocular haemorrhage (including ghost cells), leakage of lens protein or lens particles and vascular malformation or thrombosis.\n\n(13) having growth of new blood vessels (neovascularisation) of the iridocorneal angle due to a condition or procedure involving the affected eye from the specified list of conditions or procedures, before the clinical worsening of open-angle glaucoma;\n\nNote: specified list of conditions or procedures is defined in the Schedule 1 - Dictionary.\n\n(14) having trauma to the affected eye before the clinical worsening of open-angle glaucoma;\n\nNote: trauma is defined in the Schedule 1 - Dictionary.\n\n(15) having sympathetic ophthalmia at the time of the clinical worsening of open-angle glaucoma;\n\nNote: sympathetic ophthalmia is defined in the Schedule 1 - Dictionary.\n\n(16) having intraocular surgery to the affected eye before the clinical worsening of open-angle glaucoma;\n\n(17) undergoing a course of therapeutic radiation for cancer, where the affected eye was in the field of radiation, before the clinical worsening of open-angle glaucoma;\n\n(18) having:\n\n(a) eye disease associated with Graves' disease; or\n\n(b) hypothyroidism\n\nwithin the 12 months before the clinical worsening of open-angle glaucoma;\n\n(19) inability to obtain appropriate clinical management for open-angle glaucoma.\n\n10 Relationship to service\n\n(1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.\n\n(2) The factors set out in subsections 9(10) to 9(19) apply only to material contribution to, or aggravation of, open-angle glaucoma where the person's open-angle glaucoma was suffered or contracted before or during (but did not arise out of) the person's relevant service.\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nIn this Statement of Principles:\n\n(1) if a factor referred to in section 9 applies in relation to a person; and\n\n(2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(3) of the VEA;\n\nthen the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.\n\n \n\n \n\nSchedule 1 - Dictionary \n\nNote: See Section 6\n\n1 Definitions\n\nIn this instrument:\n\n episcleritis means acute or chronic inflammation of the superficial, episcleral layer of the eye ball.\n\n equivalent glucocorticoid therapy means a glucocorticoid in the following table, at the doses specified in the table, or a therapeutically equivalent dose of another glucocorticoid:\n\n \n\n| Glucocorticoid | Minimum cumulative
dose (milligrams)
| Minimum average
rate (milligrams/day) |\n| --- | --- | --- |\n| betamethasone | 60 | 2 |\n| cortisone | 1,875 | 62.5 |\n| dexamethasone | 50 | 1.67 |\n| methylprednisolone | 300 | 10 |\n| paramethasone | 150 | 5 |\n| prednisone | 375 | 12.5 |\n| prednisolone | 375 | 12.5 |\n| triamcinolone | 300 | 10 |\n\n\n equivalent inhaled glucocorticoid means:\n\n(a) 8,000 micrograms of triamcinolone;\n\n(b) 1,600 micrograms of budesonide;\n\n(c) 1,000 micrograms of fluticasone; or\n\n(d) a therapeutically equivalent dose of another inhaled glucocorticoid.\n\n glucocorticoid therapy as specified means:\n\n(a) taking:\n\n(i) hydrocortisone orally, by injection, or per rectum:\n\n1. to a cumulative dose of at least 1,500 milligrams; and\n2. at a minimum dose rate averaging 50 milligrams per day; or\n\n\n(ii) equivalent glucocorticoid therapy orally, by injection, or per rectum; or\n\n(b) inhaling at least 1,600 micrograms of beclomethasone, or equivalent inhaled glucocorticoid, daily for at least four weeks; or\n\n(c) using a topical ocular glucocorticoid to the affected eye daily for at least two weeks; or\n\n(d) using an intranasal glucocorticoid at above the maximum therapeutic dosage level daily for at least four weeks; or\n\n(e) having an intraocular or periocular glucocorticoid injection to the affected eye; or\n\n(f) applying a topical glucocorticoid to the face daily for at least four weeks; or\n\n(g) applying a high or very high potency topical glucocorticoid to at least 20% of total skin surface area, daily, for at least four weeks.\n\nNote: equivalent glucocorticoid therapy, equivalent inhaled glucocorticoid and high or very high potency topical glucocorticoid are also defined in the Schedule 1 - Dictionary.\n\n high or very high potency topical glucocorticoid means:\n\n(a) betamethasone dipropionate 0.05%;\n\n(b) betamethasone valerate 0.1%;\n\n(c) clobetasol proprionate 0.05%;\n\n(d) diflucortolone valerate 0.1%;\n\n(e) fluocinolone acetonide 0.025%; or\n\n(f) another topical glucocorticoid of equivalent potency.\n\n MRCA means the Military Rehabilitation and Compensation Act 2004.\n\n open-angle glaucoma—see subsection 7(2).\n\n relevant service means:\n\n(a) eligible war service (other than operational service) under the VEA;\n\n(b) defence service (other than hazardous service and British nuclear test defence service) under the VEA; or\n\n(c) peacetime service under the MRCA.\n\nNote: MRCA and VEA are also defined in the Schedule 1 - Dictionary.\n\n scleritis means acute or chronic inflammation that affects the white outer coating of the eye ball.\n\n specified list of conditions or procedures means:\n\n(a) carotid endarterectomy;\n\n(b) diabetic retinopathy;\n\n(c) intraocular surgery;\n\n(d) intraocular tumour;\n\n(e) carotid artery disease;\n\n(f) radiotherapy;\n\n(g) retinal detachment;\n\n(h) retinal vascular occlusion;\n\n(i) retinal vasculitis; or\n\n(j) another acquired condition causing posterior segment ischaemia.\n\n sympathetic ophthalmia means the presence of uveitis in both eyes following:\n\n(a) intraocular surgery to one eye; or\n\n(b) trauma to one eye.\n\nNote: trauma is also defined in the Schedule 1 - Dictionary.\n\n terminal event means the proximate or ultimate cause of death and includes the following:\n\n(a) pneumonia;\n\n(b) respiratory failure;\n\n(c) cardiac arrest;\n\n(d) circulatory failure; or\n\n(e) cessation of brain function.\n\n trauma means:\n\n(a) blunt or penetrating physical injury; or\n\n(b) chemical, thermal or radiation injury;\n\n that results in intraocular inflammation, intraocular bleeding or other intraocular tissue disruption.\n\n uveitis means acute or chronic inflammation of the vascular middle coat of the eye ball, comprising the iris, ciliary body and choroid. This definition includes choroidal effusion.\n\n VEA means the Veterans' Entitlements Act 1986.\n\n \n\n \n","sortOrder":0}],"analysis":{"flash_summary":{"complexity_score":6,"scope_assessment":{"changed":true,"description":"This instrument expressly repeals the 2012 Statement (s4) and updates scope and definitions: it expressly includes normal‑tension glaucoma (s7(2)(b)) and death contributed to by glaucoma (s7(5)); it sets detailed glucocorticoid exposure thresholds and multiple routes of administration in the Schedule; it separates criteria for initial onset and for clinical worsening/material contribution with a service‑relation rule (s9; s10(2)); and it adds 'inability to obtain appropriate clinical management' as a factor (s9(19)). These changes narrow or expand eligibility in specific, clinically defined ways compared with the prior instrument."},"complexity_factors":["Detailed medical and pharmacological thresholds for glucocorticoid exposure (Schedule 1: 'glucocorticoid therapy as specified', cumulative doses and equivalent inhaled/topical doses) increase evidentiary and clinical complexity.","Two temporal paths: factors qualifying for initial clinical onset (s9(1)–s9(9)) and separate factors for clinical worsening or material contribution (s9(10)–s9(19)), with different linking rules (s10(2)).","Numerous clinical conditions and procedures listed as qualifying factors (uveitis, scleritis, neoplasms, neovascularisation, intraocular surgery, radiotherapy, trauma, sympathetic ophthalmia, thyroid-related eye disease), requiring specific medical documentation (s9).","Cross‑references to other Statements of Principles where a factor refers to another injury/disease (s11) create dependency on other instruments and potential interpretive interaction.","Precise statutory framing of burden/standard of proof ('balance of probabilities') and requirement that the factor be related to 'relevant service' (s8, s10) imposes legal evidentiary constraints on medical findings.","Inclusion of death from open‑angle glaucoma via contribution to a terminal event (s7(5) and Schedule definition of 'terminal event') expands application to cause‑of‑death assessments.","Repeal of the earlier 2012 Statement (s4) and commencement timing (s2) mean practitioners and decision makers must apply the updated definitions and thresholds from the new instrument.","Technical definitions throughout the Schedule (e.g. 'trauma', 'sympathetic ophthalmia', 'specified list of conditions or procedures') require precise clinical interpretation and record linkage."],"plain_english_summary":"This Statement of Principles (No. 50 of 2021) replaces the 2012 instrument and sets the medical criteria used to decide, on the balance of probabilities, whether open‑angle glaucoma (including normal‑tension glaucoma) or related death is connected to a veteran’s relevant service under the VEA or MRCA. It lists qualifying medical factors (for example certain glucocorticoid therapies, eye inflammation, trauma, surgery, radiotherapy, neoplasms, thyroid disease, or inability to obtain appropriate care), timing rules for onset or worsening, and precise definitions used to assess entitlement."},"kimi_summary":{"content_quality":"ok","complexity_score":6,"scope_assessment":{"changed":false,"description":"This is a straightforward reissue/replacement of a 2012 Statement of Principles with the same scope. It updates the medical criteria based on current evidence but does not expand beyond the original purpose of determining service connection for open-angle glaucoma in veterans. The structure mirrors the standard template used for all RMA Statements of Principles."},"complexity_factors":["19 distinct factors with specific temporal requirements (e.g., 'within 3 months', 'within 12 months', 'at the time of')","Complex nested definitions: 'glucocorticoid therapy as specified' requires cross-referencing 3 sub-definitions (equivalent glucocorticoid therapy, equivalent inhaled glucocorticoid, high or very high potency topical glucocorticoid)","Detailed dosage tables with minimum cumulative doses and daily rates for 8 different glucocorticoid medications","Dual application structure: factors 1-9 for clinical onset vs factors 10-18 for clinical worsening, with factor 19 applying to both","Conditional limitation in section 10(2) restricting factors 10-18 to pre-existing conditions only","Cross-referencing mechanism in section 11 requiring consultation of other Statements of Principles when factors refer to other diseases","Medical terminology requiring specialist knowledge (e.g., 'iridocorneal angle', 'neovascularisation', 'trabecular meshwork melanoma', 'ghost cells')","Specific exclusion of congenital/infantile glaucomas and inclusion of normal tension glaucoma in the definition"],"plain_english_summary":"This instrument sets the medical rules for deciding whether Australian veterans and current/former defence personnel qualify for compensation for open‑angle glaucoma or death from it. It replaces the 2012 rules and requires proof, on the balance of probabilities, that specified medical factors link the glaucoma to service.\n\nIt lists 19 factors (examples include steroid use, eye inflammation, surgery or trauma), with several applying only to worsening of pre‑existing glaucoma. It functions as the gatekeeper for glaucoma-related claims."},"flash_summary_failed":{"failed":true,"reason":"A positive credit balance is required for all requests, including BYOK, so fallback providers remain available. Add credits at https://vercel.com/d?to=%2F%5Bteam%5D%2F%7E%2Fai%3Fmodal%3Dtop-up to continue.","source":"analysis-cron"}},"importantCases":[],"_links":{"self":"/api/acts/statement-of-principles-concerning-open-angle-glaucoma-balance-of-probabilities-no-50-of-2021","history":"/api/acts/statement-of-principles-concerning-open-angle-glaucoma-balance-of-probabilities-no-50-of-2021/history","analysis":"/api/acts/statement-of-principles-concerning-open-angle-glaucoma-balance-of-probabilities-no-50-of-2021/analysis","conflicts":"/api/acts/statement-of-principles-concerning-open-angle-glaucoma-balance-of-probabilities-no-50-of-2021/conflicts","importantCases":"/api/acts/statement-of-principles-concerning-open-angle-glaucoma-balance-of-probabilities-no-50-of-2021/important-cases","documents":"/api/acts/statement-of-principles-concerning-open-angle-glaucoma-balance-of-probabilities-no-50-of-2021/documents"}}